FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology. Disclosed is an oligonucleotide to allow skipping of two or more exons of dystrophin pre-mRNA. Also disclosed is a composition to enable skipping of two or more exons of dystrophin pre-mRNA, a method and use of the oligonucleotide and composition for preventing, slowing down, alleviating and / or treating Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).
EFFECT: present invention may find further application in the treatment of various diseases caused by mutations in the dystrophin gene.
5 cl, 5 dwg, 6 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
OLIGONUCLEOTIDE FOR TREATMENT OF PATIENTS WITH MUSCULAR DYSTROPHY | 2013 |
|
RU2789279C2 |
SYSTEM OF TARGETED SPLICING CHANGES IN MARK2 GENE | 2023 |
|
RU2810907C1 |
ANTISENSE NUCLEIC ACIDS | 2011 |
|
RU2567664C2 |
DEEP GLYCATION END PRODUCTS RECEPTOR MODULATORS AND MODULATION | 2020 |
|
RU2820247C2 |
ANTISENSE NUCLEIC ACIDS | 2012 |
|
RU2619184C2 |
ANTISENSE NUCLEIC ACIDS | 2018 |
|
RU2681470C1 |
ANTISENSE NUCLEIC ACIDS | 2012 |
|
RU2651468C1 |
ANTISENSE NUCLEIC ACIDS | 2015 |
|
RU2702424C2 |
ANTISENSE NUCLEIC ACIDS | 2015 |
|
RU2730681C2 |
NEW METHOD OF TREATING RETINITIS PIGMENTOSA | 2020 |
|
RU2817702C2 |
Authors
Dates
2018-12-11—Published
2013-07-03—Filed